NDA 210951 · Janssen Biotech
Erleada
Apalutamide · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Feb 14, 2018
Approved uses
5
Original approval plus efficacy supplements
Registered trials
138
30 Phase 3, 39 recruiting
FAERS reports
12,037
7,475 serious, 1,541 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 2, 2026.
ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. ( 1 ) non-metastatic castration-resistant prostate cancer. ( 1 )
Mechanism: Apalutamide is an Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. Apalutamide inhibits AR nuclear translocation, inhibits DNA binding, and impedes AR-mediated transcription. A major metabolite, N-desmethyl apalutamide, is a less potent inhibitor of AR, and exhibited one-third the activity of apalutamide in an in vitro transcriptional reporter assay. Apalutamide administration caused decreased tumor cell proliferation and increased apoptosis leading to decreased tumor volume in mouse xenograft models of prostate cancer.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2023 Supplement 14 · Efficacy LetterLabel
- Sep 7, 2021 Supplement 6 · Efficacy LetterLabel
- Nov 20, 2020 Supplement 4 · Efficacy · priority review LabelLetter
- Sep 17, 2019 Supplement 1 · Efficacy · priority review LabelLetter
- Feb 14, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
2 products under this application
- ERLEADA · APALUTAMIDE 60MG · TABLET, ORAL · Prescription · TE AB
- ERLEADA · APALUTAMIDE 240MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Apalutamide" as an intervention, any sponsor and status, largest first.
- A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06320067 · 3,360 participants (planned) · Start Jun 11, 2024 · Primary completion Apr 2031
Drug: Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI) and 1 more · For: Prostate Cancer Metastatic
Sites: Barnsley, United Kingdom; Cambridge, United Kingdom; Exeter, United Kingdom · 18 sites in all
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03767244 · 2,517 participants · Start Jun 11, 2019 · Primary completion Dec 1, 2026
Drug: Apalutamide; Androgen Deprivation Therapy (ADT) and 1 more · For: Prostatic Neoplasms
Sites: La Jolla, California; Los Angeles, California; Orange, California · 203 sites in all
- Intermittent Androgen Deprivation Therapy in the Era of AR Pathway InhibitorsPivotal-lookingRecruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT05974774 · 1,600 participants (planned) · Start May 23, 2025 · Primary completion May 23, 2035
Drug: iMAB; cMAB · For: Prostate Cancer
Sites: Copenhagen, Denmark; Caen, France; Grenoble, France · 9 sites in all
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASPivotal-lookingActive, not recruiting
Aragon Pharmaceuticals, Inc.Industry
NCT02531516 · 1,503 participants · Start Nov 19, 2015 · Primary completion Mar 1, 2027
Drug: Apalutamide; Bicalutamide and 3 more · For: Prostatic Neoplasms
Sites: Homewood, Alabama; Chandler, Arizona; Scottsdale, Arizona · 263 sites in all
- Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT07751133 · 1,500 participants (planned) · Start Aug 28, 2026 · Primary completion Aug 1, 2029
Drug: Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy · For: Prostate Cancer; mHSPC; mCRPC
Sites: Huddersfield, United Kingdom; Manchester, United Kingdom; Sutton, United Kingdom · 4 sites in all
- Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialPivotal-lookingRecruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT06931340 · 1,260 participants (planned) · Start Dec 1, 2025 · Primary completion Nov 11, 2031
Drug: Androgen Therapy; Apalutamide and 1 more · For: Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
Sites: Tucson, Arizona; Dublin, California; Fremont, California · 214 sites in all
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerPivotal-lookingActive, not recruiting
Aragon Pharmaceuticals, Inc.Industry
NCT01946204 · 1,207 participants · Start Oct 14, 2013 · Primary completion May 19, 2017
Drug: Apalutamide; Placebo · For: Prostatic Neoplasms
Sites: Birmingham, Alabama; Anchorage, Alaska; Chandler, Arizona · 379 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash1,336
- fatigue1,240
- death1,203
- hot flush922
- product dose omission issue450
- asthenia443
- diarrhoea421
- dizziness376
- arthralgia371
- off label use365
- fall354
- decreased appetite330
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 363 |
| 2019 | 838 |
| 2020 | 1,248 |
| 2021 | 1,023 |
| 2022 | 2,105 |
| 2023 | 1,761 |
| 2024 | 1,837 |
| 2025 | 1,811 |
| 2026 | 1,041 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Erleada (Apalutamide)
2024 spending
$1.39B
Beneficiaries
13,253
95,580 claims
Per beneficiary
$104,603
$233.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $469,314,125 |
| 2021 | $734,682,218 |
| 2022 | $877,671,428 |
| 2023 | $1,057,789,083 |
| 2024 | $1,386,301,873 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Chi KN, Chowdhury S, Bjartell A, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
Taplin ME, Gleave M, Shore ND, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
El-Taji O, Taktak S, Jones C, et al. · JAMA Oncol 2024 · Systematic Review, Meta-Analysis
- Apalutamide and Overall Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, et al. · Eur Urol 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.